Senile amyloidosis has often been viewed as an uncommon disorder which differs from other forms of amyloid only with respect to patient age and organ distribution. In recent years, it has become increasingly evident that amyloidosis represents a family of diseases, each member of which may be characterised by unique amyloid fibril proteins, and that the socalled senile amyloidoses are rather distinct members of this family. It is now clear that amyloidosis associated with aging is very common and, although it shares histochemical and morphological features with other forms of amyloidosis, it possesses unique structural, biochemical, and immunological characteristics. Moreover, there is evidence that amyloid deposits present in heart, brain, pancreas, and other tissues of elderly patients may be distinguished from one another on the basis of unique fibrillar appearance and structure, biochemical properties, and protein components. This review summarises recent knowledge regarding the unique characteristics and apparent clinical significance of age-related amyloidosis associated with cardiovascular, pancreatic, and cerebrovascular tissues.
Senile amyloid ofthe heart
The frequency of amyloid deposition in the hearts of elderly patients and its significance have been studied by a number of investigators over the past [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] years.'=" Since antibody specific for this type of amyloid has not been available until recently, all of these studies have been based on histochemical staining, and variations in the results have been related to the patient population studied and to the Received for publication 8 April 1980 histochemical criteria used. The published prevalence in patients over 70 years of age has varied from 2 %3 to greater than 80 %.9 In the former series, methyl-violet staining of heart sections was carried out only in those tissues which appeared to contain amyloid by initial screening by haematoxylin and eosin; in the latter study, thioflavine-S was used as an indicator of amyloid deposition, a method found by some investigators to lack specificity for amyloid fibrilS.8 12 1 Amyloid deposits in the heart are a common occurrence in elderly patients.
2 The prevalence increases with each decade above the age of 60.
3 The earliest findings are generally manifest as small deposits on the subendocardial surface of the atrium, the left being more common than the right.
4 With increasing age, there is increasing likelihood of involvement of the ventricles (in addition to atria), with an apparent gradual progression from small ventricular foci to larger foci and eventually to diffuse ventricular infiltration.
5 The involvement of extracardiac tissues is rare in cardiac amyloidosis limited to the atria but increases significantly when moderately large foci or diffuse involvement of the ventricles are present. In such patients, however, the extracardiac deposition tends to be limited to the aorta, pulmonary vessels, and pulmonary alveolar septa, with occasional foci in small and medium-sized vessels of other tissues. Despite the fact that the brain and the pancreas are frequently found to contain amyloid in elderly patients, there does not appear to be a close correlation between involvement of the heart and these other organs.
Although Although both types may coexist in the same heart tissue, the data suggest that they are pathogenically unrelated. The use of antiAScI antiserum has provided the first opportunity to compare the biochemical nature of one form of age-dependent amyloid (SCA) with other wellknown types of age-dependent and age-independent amyloids. The failure of this antiserum to identify pancreatic amyloid deposits in elderly diabetics or cerebral amyloid deposits in patients with Alzheimer's disease indicates that amyloid deposits relating to the aging process may differ in their biochemical composition on the basis of organ localisation. This finding would be in contrast to that observed in generalised primary and secondary amyloidosis, in which the amyloid fibrils from different organs from the same individual are identical in their chemical composition.
The Table summarises some of the differences between senile amyloids of the heart and other forms of cardiac amyloidosis.
Comparison ofsenile amyloids ofthe heart with otherforms ofcardiac amyloidosis The connecting peptide (C-peptide) of proinsulin has also been proposed as the substratum for islet amyloid.31 However, this possibility appears unlikely since certain amino acids such as tyrosine29 and cystine (Westermark P. unpublished observations), which are not present in the C-peptide, seem to occur in islet amyloid.
Amyloid also occurs in some polypeptide hormone-producing tumours, especially those making insulin, calcitonin, and growth hormone.32 It is likely that the amyloid of the islets of Langerhans and the amyloid of the insulin-producing tumours are chemically identical. It is also probable that the amyloids of different amyloid-producing tumours share pathogenic similarities. The finding that a major fibril protein of the amyloid associated with medullary carcinoma of the thyroid is probably procalcitonin33 may thus have implications for amyloid of the pancreatic islets. It seems very likely that islet amyloid contains a polymer of preproinsulin or a portion thereof, although it does not appear to contain intact insulin or C-peptide.
The antigenic properties of islet amyloid have been studied by immunodiffusion and immunofluorescent techniques. This form of amyloid does not react with antisera against protein AA, several different proteins of immunoglobulin origin, or the so-called void volume material (Vo) of amyloid. Antisera to AScI and to the fibril subunit protein of the amyloid of medullary carcinoma of the thyroid, protein AEt, also fail to react with islet amyloid.'6 Thus the amyloid fibrils of the islets of Langerhans are immunologically different from other amyloid fibrils. On the other hand, the water-soluble P-component (protein AP) seems to be present in the amyloid of the islets, as in almost all other amyloids irrespective of type. 34 The cause of islet amyloid and its influence on islet function are important unanswered questions. The islet amyloid has been mentioned as a possible cause of diabetes, since the substance might form a barrier between the f-cells and the capillaries. However, in many cases of maturity onset diabetes, the amount of amyloid is insufficient to account for a significant influence on the total islet cell mass. 21 On the other hand, despite rather small amounts of amyloid in pancreatic islets, severe cell membrane injuries are present in most 3-cells25 with the result that there is a substantial reduction of the normal f-cell mass in this condition.2 ' We believe that islet amyloid does not cause diabetes but rather results from it. It is highly probable that maturity onset diabetes reflects f-cell dysfunction, but it is possible only to speculate about the nature of this dysfunction. It is well known that the islets in this disease have a partial inability to secrete synthesised insulin, an abnormality that may lead to stagnation of synthesized products (preproinsulin ?) with subsequent polymerisation into amyloid fibrils. Partial degradation of such precursors probably occurs in a manner that has been postulated for other amyloids.5 36 SUMMARY Islet amyloidosis is commonly found in elderly persons, but the degree of islet involvement is most extensive in patients with maturity onset diabetes mellitus. Morphological, biochemical, and immunological studies indicate that this form of amyloid has certain unique properties. Although its chemical structure is unknown, there is strong evidence that the fibrils are produced by the f-cells and may represent polymerisation products of a portion of preproinsulin synthesised by these cells. Islet amyloid does not appear to cause diabetes but probably results from dysfunction of the f-cells.
Cerebrovascular amyloidosis
In senile dementia, especially when associated with Alzheimer's disease, the occurrence of senile plaques in the cortex of the brain is a typical finding. The mature plaque has a unique morphology with a peripheral zone which contains neuronal processes and glia cells while the central core is free of cells. It has long been known that this core has staining properties of amyloid, ' and its electr-on m-licroscopic appearance is also typical of amyloid.38 The nature of the amyloid material is unknown and has been a subject of speculation.39 Histochemically, it has been compared to the 'apudamyloid' (amyloid of endocrine origin), since it has a low content of aromatic amino acids. 40 The formation of amyloid is probably a secondary phenomenon, since primitive plaques do not contain any detectable amyloid. 41 The neurofibrillary tangles, which occur intracellularly in neurons of Alzheimer's disease and, to some degree, in senile dementia, also show staining properties of amyloid.39 The tangles often, but not always, occur simultaneously with senile plaques. In spite of the similarity in staining properties with Congo red, the tangles have a morphological appearance which resembles microtubules and is quite different from the fibrils of the plaques.42 In fact it has recently been shown that antiserum to neurotubular antigens cross-reacts with the neurofibrillar tangles. 43 The occurrence of amyloid deposits in vessels of the brain and the meninges (Congophilic angiopathy) in elderly persons is also a well-known phenomenon. The amyloid infiltration is located predominantly in the media of affected vessels. Such Congophilic angiopathy is seen almost uniformly in Alzheimer's disease and in senile dementia of the Alzheimer type.44 There is also a distribution correlation between angiopathy and senile plaques but not between angiopathy and the neurofibrillary tangles.44 Some investigators have found a correlation between the Congophilic angiopathy and amyloidosis of the cardiovascular system,45 but this observation has been denied by others (Cameron R, Brun A, personal communication). It seems clear, however, that the senile cardiac amyloid, which to some degree affects vessels outside the heart, is a disease different from the cerebrovascular amyloid since protein AScI is not present in the latter. 17 Whether the fibrils of the senile plaques and of the Congophilic angiopathy are chemically identical is unknown. It has been proposed that the amyloid of the senile plaques has a local origin, while the amyloid of the Congophilic angiopathy is derived from serum proteins.39
Amyloid is usually found in cortical plaqLIcS LISSOCiated with senile dementia and Alzheimcr's disease. Congophilic angiopathy of the brain and meninges is also commonly present in patients with these disorders. The chemical nature and pathogen-sis of these forms of amyloid are unknown, but it appears likely that their association with dernentiat is a S~Ontary, rather than a prionary, pi-.1clomenon.
Conclusion
Senile amyloidosis includes a protean group of diseases which, while sharing some features common to all forms of amyloidosis, appear to be unique with respect to tissue localisation, ultrastructural appearance, extraction characteristics, and protein components. To date, only generalised senile cardiac amyloid (SCA) has yielded a specific protein comparable to ALA or AL,< in primary or myeloma/ macroglobulin associated amyloid, AA in secondary amyloid, or AEt in amyloid associated with medullary carcinoma of the thyroid. Although there is speculation that an insulin-related protein is a major component of pancreatic islet amyloid, conclusive evidence is lacking. It appears likely that age-related amyloid causes direct clinical effects in only a small percentage of patients, but the true clinical significance of these forms of amyloid will not be known until biochemical methods of detecting them ante mortem are found.
